Clinical and mycological characteristics of oropharyngeal candidiasis in patients receiving long-term inhaled glucocorticosteroids..

Authors

  • Medzhidova Valikiz Gasanbekovna
  • Alidibirova Patimat Nasrulaevna
  • Bilalova Saida Rashithanovna
  • Velieva Jamila Alievna
  • Tailova Luiza Gasanguseynovna
  • Djanakaeva Djennet Narimanovna
  • Shemshedinova Aina Ibragimovna
  • Ahmedsalimova Aljanat Gusenovna
  • Muslimova Saniyat Magomedrasulovna
  • Guseynova Aminat Timurovna

DOI:

https://doi.org/10.63682/jns.v15i1s.10458

Keywords:

oropharyngeal candidiasis; inhaled glucocorticosteroids; Candida albicans; bronchial asthma; chronic obstructive pulmonary disease; mycological examination; risk factors; oral mucosa

Abstract

Oropharyngeal candidiasis is one of the most common local complications of long-term therapy with inhaled glucocorticosteroids. Despite the high clinical significance of this pathology, the issues of its prevalence, clinical manifestations and species composition of pathogens in patients with chronic respiratory diseases remain insufficiently studied. The purpose of the study. To study the clinical and mycological features of oropharyngeal candidiasis in patients receiving inhaled glucocorticosteroids for a long time. Materials and methods. A single-stage observational study was conducted with the participation of 120 patients who had been receiving inhaled glucocorticosteroids for bronchial asthma and chronic obstructive pulmonary disease for a long time. All the examined patients underwent a clinical examination of the oral and oropharyngeal mucosa, medical history collection and mycological examination of smears followed by identification of fungi of the genus Candida. Statistical data processing was performed using the IBM SPSS Statistics 26.0 program, and differences were considered statistically significant at p < 0.05. Results. Oropharyngeal candidiasis was diagnosed in 34 (28.3%) patients. The most common clinical form was pseudomembranous candidiasis (58.8%). Mycological examination revealed Candida albicans (70.6%) most frequently, Candida glabrata (14.7%), Candida tropicalis (8.8%) and Candida parapsilosis (5.9%) less frequently. It has been established that the development of candidal infection is significantly associated with the use of high doses of inhaled glucocorticosteroids, the duration of therapy for more than five years and non-compliance with preventive measures. The use of a spacer and mouthwash after inhalation were accompanied by a decrease in the incidence of candidiasis. Conclusion. Long-term therapy with inhaled glucocorticosteroids is a significant risk factor for the development of oropharyngeal candidiasis. A comprehensive clinical and mycological examination of patients makes it possible to detect the disease in a timely manner, and compliance with preventive measures helps to reduce the frequency of candidal lesions of the oral and oropharyngeal mucosa

Downloads

Download data is not yet available.

References

1.Pappas P.G., Kauffman C.A., Andes D.R., et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America // Clinical Infectious Diseases. 2016. Vol. 62, No. 4. P. e1–e50.

2. Arzayus-Patiño L., Benavides-Córdoba V. Non-Pharmacological Interventions to Prevent Oropharyngeal Candidiasis in Patients Using Inhaled Corticosteroids: A Narrative Review // Healthcare. 2025. Vol. 13, No. 14. Art. 1718.

3. Barnes P.J. Inhaled Corticosteroids // Pharmaceuticals. 2010. Vol. 3, No. 3. P. 514–540.

4. Williams D.M. Inhaled corticosteroids: Effects on the respiratory system // Respiratory Care. 2018. Vol. 63, No. 6. P. 655–670.

5. van Boven J.F.M., de Jong-van den Berg L.T.W., Vegter S. Inhaled corticosteroids and the occurrence of oral candidiasis: A prescription sequence symmetry analysis // Drug Safety. 2013. Vol. 36, No. 4. P. 231–236.

6. Contaldo M., Di Stasio D., Romano A., et al. Oral Candidiasis and Novel Therapeutic Strategies: Antifungals, Phytotherapy, Probiotics, and Photodynamic Therapy // Current Drug Delivery. 2023. Vol. 20, No. 4. P. 441–456.

7. Akpan A., Morgan R. Oral candidiasis // Postgraduate Medical Journal. 2002. Vol. 78. P. 455–459.

8. Calderone R.A., Clancy C.J. (Eds.). Candida and Candidiasis. 2nd ed. Washington, DC: ASM Press, 2012. 472 p.

9. Samaranayake L.P. Essential Microbiology for Dentistry. 5th ed. Edinburgh: Elsevier, 2018. 432 p.

10. Taylor M., Brizuela M., Raja A. Oral Candidiasis // StatPearls. Treasure Island (FL): StatPearls Publishing, 2025...

Downloads

Published

2026-07-14

How to Cite

1.
Valikiz Gasanbekovna M, Patimat Nasrulaevna A, Rashithanovna BS, Alievna VJ, Gasanguseynovna TL, Narimanovna DD, et al. Clinical and mycological characteristics of oropharyngeal candidiasis in patients receiving long-term inhaled glucocorticosteroids. J Neonatal Surg [Internet]. 2026 Jul. 14 [cited 2026 Jul. 18];15(1s):279-83. Available from: https://jneonatalsurg.com/index.php/jns/article/view/10458

Issue

Vol. 15 No. 1s (2026): Journal of Neonatal Surgery

Section

Original Article

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

You are free to:

  • Adapt — remix, transform, and build upon the material for any purpose, even commercially.

Terms:

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.